Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zevra TherapeuticsSTU:1GDA +0.82%69 Days Payable is 766.59 as of Jun. 2026, which is 137% above its 10-year median of 323.61. GuruFocus rates STU:1GDA with a GF Score™ of 69/100 and a GF Value™ of €17.92 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 704 Biotechnology companies, Zevra Therapeutics ranks better than 80.97% on this metric.
The historical rank and industry rank for Zevra Therapeutics's Days Payable or its related term are showing as below:
STU:1GDA'
s Days Payable Range Over the Past 10 Years
Min: 149.79 Med: 323.61 Max: 3392.69
Current: 553.76
During the past 13 years, Zevra Therapeutics's highest Days Payable was 3392.69. The lowest was 149.79. And the median was 323.61.
STU:1GDA's Days Payable is ranked better than 80.97% of 704
companies
in the Biotechnology industry
Industry Median: 112.83
vs STU:1GDA: 553.76
Zevra Therapeutics's Days Payable
increased
from Jun. 2025 (0.00) to Jun. 2026 (766.59).
It may suggest that Zevra Therapeuticsdelayed paying its suppliers.
The historical data trend for Zevra Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1GDA vs TECX, RLMD, ALT: Days Payable Comparison
For the Biotechnology subindustry, Zevra Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zevra Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Zevra Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Zevra Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zevra Therapeutics (STU:1GDA) has a Days Payable of 766.59 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zevra Therapeutics and its competitors. This is 137% above median its historical median of 323.61. Over the past decade, Zevra Therapeutics' Days Payable has ranged from 149.79 to 3,392.69. According to the industry distribution chart, Zevra Therapeutics ranks #134 out of 704 companies in the Biotechnology industry, placing it in the top 19%.
Is Zevra Therapeutics' Days Payable too high?
Zevra Therapeutics' current Days Payable of 766.59 is 137% above median its 10-year median of 323.61. Over the past 10 years, this metric has ranged from a low of 149.79 to a high of 3,392.69. The Biotechnology industry median Days Payable is 112.83. Zevra Therapeutics' value of 766.59 is 579.4% above this industry median. Based on the distribution chart, Zevra Therapeutics ranks #134 out of 704 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zevra Therapeutics has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zevra Therapeutics' Days Payable compare to TECX and RLMD?
According to the Biotechnology industry distribution chart, Zevra Therapeutics ranks #134 out of 704 companies for Days Payable. This places Zevra Therapeutics in the top 19% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.83. Zevra Therapeutics' value of 766.59 is 579.4% above this benchmark. Historically, Zevra Therapeutics' own Days Payable has ranged from 149.79 to 3,392.69 over the past decade. While the company's 10-year median is 323.61 vs. the industry median of 112.83, Zevra Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.83, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zevra Therapeutics's current Days Payable of 766.59 is 579.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zevra Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 112.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zevra Therapeutics's current Days Payable is 766.59, which is 137% above median its own 10-year median of 323.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zevra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zevra Therapeutics (STU:1GDA) is currently considered Possible Value Trap. The stock's GF Value™ is €17.92, compared to a current price of €9.80 — trading 45.3% below its estimated fair value. The current Days Payable is 766.59, which is 137% above median its 10-year median of 323.61 and 579.4% above the Biotechnology industry median of 112.83. Zevra Therapeutics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Zevra Therapeutics (STU:1GDA), the current Days Payable is 766.59 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zevra Therapeutics (STU:1GDA) Overvalued in 2026?
Based on GuruFocus' analysis, Zevra Therapeutics stock appears to be undervalued.
The current stock price of €9.80 is trading 45.3% below its estimated GF Value™ of €17.92.
GuruFocus considers Zevra Therapeutics to be Possible Value Trap.
Key valuation signals for STU:1GDA:
Days Payable: 766.59 (137% above median its 10-year median of 323.61)
GF Value™: €17.92 vs. price of €9.80 (45.3% below fair value)
Industry Position: 579.4% above the Biotechnology median (#134 of 704)
No single metric tells the full story. See the STU:1GDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
69GF Score
Get the complete analysis for STU:1GDA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1GDA has been successfully added to your 
